Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528944 | 1.00 | MTNR1A (0.43) | MTNR1AMTNR1BCHRM2CHRM4CHRM1 | |
| SCHEMBL3528943 | 1.00 | MTNR1A (0.43) | MTNR1AMTNR1BCHRM2CHRM4CHRM1 | |
| SCHEMBL3526071 | 0.85 | CHRM2 (0.46) | MTNR1ACHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3526076 | 0.85 | CHRM2 (0.46) | MTNR1ACHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3526073 | 0.85 | CHRM2 (0.46) | MTNR1ACHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2365390 | 0.82 | MTNR1A (0.37) | MTNR1AMTNR1BCHRM2CHRM4CHRM1 | |
| SCHEMBL3524895 | 0.78 | KMT2A (0.47) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3524892 | 0.78 | KMT2A (0.47) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3524896 | 0.78 | KMT2A (0.47) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1735281 | 0.77 | MTNR1A (0.42) | MTNR1AMTNR1BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | claimed |
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2084152-A2 | SUBSTITUTED 4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2008058867-A2 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | TAAR1, TAAR5, TACR1 | MTNR1A 29/4885MTNR1B 50/4885CHRM2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.